Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Purdue Feels The Pain With $700 Million Settlement For Misleading OxyContin Promos

This article was originally published in The Pink Sheet Daily

Executive Summary

Purdue pleads guilty to illegally promoting and selling the painkiller, ending an investigation by the U.S. Attorney’s Office in Virginia.
Advertisement

Related Content

Panel Abuses Purdue Over OxyContin
Panel Abuses Purdue Over OxyContin
Purdue’s OxyContin Tablets AC Review To Focus On Risk Management Strategies
Purdue’s OxyContin Tablets AC Review To Focus On Risk Management Strategies
New Jersey Launches Investigation of Amgen’s Enbrel Marketing Practices
New Jersey Launches Investigation of Amgen’s Enbrel Marketing Practices
U.Va. Materials On Topamax Alcohol Study Draw Public Citizen’s Ire
U.Va. Materials On Topamax Alcohol Study Draw Public Citizen’s Ire
Serono Labs Pleads Guilty To Criminal Conspiracy Charges In Serostim Case
Serono Labs Pleads Guilty To Criminal Conspiracy Charges In Serostim Case

Topics

Advertisement
UsernamePublicRestriction

Register

PS066017

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel